Karyopharm Therapeutics Inc. (NASDAQ:KPTI) – Analysts at Jefferies Group increased their FY2016 earnings per share (EPS) estimates for Karyopharm Therapeutics in a research note issued on Monday. Jefferies Group analyst B. Abrahams now forecasts that the firm will earn ($2.97) per share for the year, up from their prior estimate of ($3.17). Jefferies Group currently has a “Buy” rating and a $12.00 target price on the stock. Jefferies Group also issued estimates for Karyopharm Therapeutics’ Q4 2016 earnings at ($0.69) EPS, FY2017 earnings at ($2.78) EPS, FY2019 earnings at ($1.65) EPS and FY2020 earnings at ($0.22) EPS.

Several other equities analysts have also issued reports on the company. Zacks Investment Research upgraded Karyopharm Therapeutics from a “hold” rating to a “buy” rating and set a $11.00 price objective for the company in a research report on Friday. Canaccord Genuity reiterated a “buy” rating on shares of Karyopharm Therapeutics in a research report on Tuesday. HC Wainwright reiterated a “buy” rating on shares of Karyopharm Therapeutics in a research report on Tuesday. Wedbush reiterated an “outperform” rating and issued a $14.00 price objective on shares of Karyopharm Therapeutics in a research report on Tuesday. Finally, Leerink Swann reiterated an “outperform” rating and issued a $18.00 price objective on shares of Karyopharm Therapeutics in a research report on Friday, October 7th. One equities research analyst has rated the stock with a sell rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $15.47.

Earnings History and Estimates for Karyopharm Therapeutics (NASDAQ:KPTI)

Karyopharm Therapeutics (NASDAQ:KPTI) opened at 9.93 on Thursday. The company’s market cap is $357.37 million. The company’s 50-day moving average is $8.71 and its 200-day moving average is $8.28. Karyopharm Therapeutics has a 12 month low of $4.83 and a 12 month high of $19.41.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its quarterly earnings results on Monday, November 7th. The company reported ($0.69) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.81) by $0.12.

Several large investors have recently added to or reduced their stakes in the stock. California State Teachers Retirement System boosted its stake in Karyopharm Therapeutics by 0.6% in the third quarter. California State Teachers Retirement System now owns 49,844 shares of the company’s stock worth $485,000 after buying an additional 300 shares during the period. ProShare Advisors LLC boosted its stake in Karyopharm Therapeutics by 1.3% in the second quarter. ProShare Advisors LLC now owns 29,655 shares of the company’s stock worth $199,000 after buying an additional 376 shares during the period. Schwab Charles Investment Management Inc. boosted its stake in Karyopharm Therapeutics by 1.5% in the second quarter. Schwab Charles Investment Management Inc. now owns 60,498 shares of the company’s stock worth $406,000 after buying an additional 882 shares during the period. BlackRock Advisors LLC boosted its stake in Karyopharm Therapeutics by 15.1% in the third quarter. BlackRock Advisors LLC now owns 11,410 shares of the company’s stock worth $111,000 after buying an additional 1,498 shares during the period. Finally, Swiss National Bank boosted its stake in Karyopharm Therapeutics by 7.3% in the second quarter. Swiss National Bank now owns 36,850 shares of the company’s stock worth $247,000 after buying an additional 2,500 shares during the period. 55.71% of the stock is owned by institutional investors.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its segment is the business of discovering, developing and commercializing drugs to treat cancer and certain other major diseases.

5 Day Chart for NASDAQ:KPTI

Receive News & Stock Ratings for Karyopharm Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc. and related stocks with our FREE daily email newsletter.